Steven I. Blum

Perioperative Nivolumab in Resectable Lung Cancer

Tina Cascone, Mark M. Awad, Jonathan Spicer et al. · New England Journal of Medicine · 2024 · 447 citations · Full text

Medicine, Oncology, Surgery +17

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

Julie R. Brahmer, Jong-Seok Lee, Tudor–Eliade Ciuleanu et al. · Journal of Clinical Oncology · 2022 · 381 citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Thierry André, Elena Élez, Heinz‐Josef Lenz et al. · The Lancet · 2025 · 179 citations

Medicine, Oncology, Immunotherapy +12

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

David Cella, Robert J. Motzer, Cristina Suárez et al. · The Lancet Oncology · 2022 · 86 citations · Full text

Medicine, Oncology, Pharmacology +9

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis

Andrew P. Yu, Hongbo Yang, Eric Q. Wu et al. · Journal of Medical Economics · 2011 · 55 citations

Medicine, Internal Medicine, Pharmacoeconomics +14